• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Onyx Pharmaceuticals

Onyx Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Research and Markets: Global Multiple Myeloma Drugs Market 2015-2019 with Celgene, J & J, Novartis, Onyx Pharmaceuticals , Sanofi & Takeda Pharmaceutical Dominating

    Research and Markets: Global Multiple Myeloma Drugs Market 2015-2019 with Celgene, J & J, Novartis, Onyx Pharmaceuticals , Sanofi & Takeda Pharmaceutical Dominating

  2. Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

    Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

  3. Research and Markets: T-Cell Lymphomas - Pipeline Review, H2 2014

    Research and Markets: T-Cell Lymphomas - Pipeline Review, H2 2014

  4. FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

  5. Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition

    Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition

  6. Our Outlook for the Credit Markets

    Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.

  7. ClearBridge Fund Prepared for Extended Rally

    The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.

  8. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.